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1INTRODUCTION
Esophageal fistulas are a major cause of morbidity and mortality
necessitating complex clinical evaluation and decision making for optimal
management. It is best treated in a specialty tertiary care setting by a
multidisciplinary team approach. Etiology of esophageal fistulas is
multifactorial and the presentation can vary from simple external cervical
esophageal fistulas to complex tracheoesophageal fistulas and
esophagopleurocutaneous fistulas.
Among patients with carcinoma esophagus, the development of
airway-esophageal fistulas alters the natural history dramatically with rapid
downhill course leading onto mortality in untreated cases.
In acquired non-malignant causes of airway-esophageal fistulas, the
patients suffer from significant morbidity due to recurrent pulmonary
sepsis.
These diseases are complex and mandates critical preoperative
evaluation for optimal management. As we are tertiary surgical center for
advanced gastrointestinal surgery, such difficult-to-manage patients are
referred from all over the state. We ventured to collect the data of all these
patients and analyze them in detail for better understanding of this
uncommon disease.
2AIM OF THE STUDY
To study the various etiological factors and   patterns of clinical
presentation of esophageal fistulas.
To study the modes of evaluation and treatment of esophageal
fistula.
To analyze the outcome of management of esophageal fistula
patients
3REVIEW OF LITERATURE
The term ‘fistula’ is an abnormal passage between a hollow or
tubular organ and the body surface or between two hollow or tubular
organs. Esophageal fistulas can be external, namely the esophagocutaneous
fistulas, internal, esopahgorespiratory fistulas or interno-external, the
esophagopleurocutaneous fistulas. Esopahgorespiratory fistula or airway-
esophageal fistula represents any communication between the esophagus
and the tracheobronchial tree.
 Broadly, esophageal fistulas can be classified based on etiology into
malignant and nonmalignant fistulas. In most of the existing literature,
4tracheoesophageal or bronchoesophageal fistulas arising due to malignant
etiology constitute majority of cases. Fistulas arising from other causes are
included in ‘nonmalignant’ category for descriptive purposes. Also, in our
department, we see only adult patients with esophageal fistulas and
pediatric cases due to congenital TEF are excluded from our study.
Malignant Airway-Esophageal Fistulas
Malignancies resulting in fistula between tracheobronchial tree and
esophagus are carcinoma esophagus, bronchogenic carcinoma, carcinoma
larynx, tracheal carcinoma, mediastinal lymphoma, and other rare causes
like erosion of metastatic nodes eroding into both organs.
Despite any etiology, the development of fistula is a life-threatening
complication [1].  It is considered to be a thoracic oncological emergency.
Irrespective of the stage of the cancer, patients developing this
complication will succumb to this disease due to continuous flow of
gastrointestinal secretions into the tracheobronchial tree resulting in
unrelenting pulmonary sepsis. Hence, early institution of aggressive
treatment is mandatory [2].
The site of fistula along the respiratory passage is tracheal, in more
than 50% cases, bronchial in up to 40% cases and a very small number
(6%) of patients will have esophagopulmonary fistulas.
5It was observed that patients who have fistula in the right bronchus
have poorer survival than patients with fistulisation into left bronchus. This
is probably due to the fact that left bronchus is anatomically close to
esophagus and for occurrence of right bronchial fistula; the disease has to
be fairly large.
The incidence of malignant esopahgorespiratory fistula is reported to
be 4.5% for carcinoma esophagus and 0.3% for lung cancers.  The
pathogenesis may be due to direct tumor invasion of the tracheobronchial
tree or it can occur as a complication of therapy like radiation,
chemotherapy or stenting or a combination ofthese [8].
Clinical features
The patients’ symptom is dominated by the presence of respiratory
complaints due to aspiration of esophageal contents. The characteristic
symptom of cough induced by swallow of oral liquids is pathognomonic
and is called the Ono’s sign. Patient can have purulent sputum and
coughing out of ingested food can also occur. Patient can be debilitated
due to loss of food intake, malignant cachexia and chronic pulmonary
sepsis. Fever can also occur. On examination, patients have florid lung
signs and appear extremely ill.
6Diagnosis
The diagnosis of this condition is usually straightforward in a patient
with characteristic symptom. However, similar symptoms can occur in
patients who have aspiration due to disordered swallowing mechanisms
which can coexist in these patients. Also, the near-total luminal occlusions
by the tumor can preclude successful endoscopy and visualization of the
fistula orifice.  Autopsy studies revealed higher incidence of fistulas in
patients with advanced cancer esophagus, thus suggesting that fistulas are
more common in patients than is usually diagnosed [1].
Barium esophagogram is usually performed in patients suspected to
have airway-esophageal fistula. It shows filling of barium in the
tracheobronchial tree. In cases where barium is aspirated into the
respiratory tract, it will be seen filling the larynx and the entire
tracheobronchial tree, a finding which helps in differentiation from TEF.
Of particular importance, it should be emphasized that gastrograffin or
high osmolar oral contrast agents should not be used in suspicious cases of
TEF. If these agents are aspirated in the respiratory tract, they result in
pulmonary congestion and necrotizing pneumonitis which may be life
threatening.
7Contrast- enhanced Computerized Tomography scan (CE CT) of the
neck, thorax with or without abdomen is done  in most patients. The
present day multislice CT with 3D reconstruction can provide us with
exquisite images of the fistula, its relation to surrounding structures
thereby aids in planning the stent deployment. It also gives information
about the primary disease, its stage and degree of sepsis in lung
parenchyma.
Management
Any treatment directed towards TEF should principally aim at
cessation of spillage of esophageal contents into the respiratory passage.
Also, many of these patients are dysphasic due to the presence of
malignant stricture in the esophagus. Therefore the goal of treatment is
largely palliative. This underlines the fact that management of these
already moribund patients should cause minimal distress to them.
Surgical treatment of malignant TEF had been done in the past and
ranged from en bloc resection of esophagus and lung to esophageal
exclusion procedures. However, the morbidity and mortality of these
patients were prohibitively high and therefore largely abandoned. Upper
gastrointestinal endoscopy with deployment of esophageal and/or airway
stents adequately achieves the therapeutic goals adding very little to the
8morbidity and mortality. Hence, endotherapy is considered the first line
treatment of this condition.
Stenting for Airway-esophageal fistulas
Before the advent of endoscopic metallic stent insertion,
conventional esophageal prosthesis was used for stenting.  Lux and Wilson
initially  reported  the  placement  of    Wilson-Cook    prosthesis  [3]  and
achieved satisfactory results. However, these conventional prosthesis are
known to migrate distally especially in a dilated esophagus and also does
not prevent food spilling around the edges of the device and entering the
respiratory tree, so-called, ‘funnel phenomenon’.
Covered self-expandable metallic stents were introduced in the mid-
1990s and have shown to have low rates of migration, low incidence of
occlusion due to tumor ingrowth and long term maintenance of adequate
patency [18].
In patients with carcinoma esophagus without any fistula into the
airway, 16 mm stents are usually deployed. In patients who have coexistent
airway-esophageal fistula, 18 mm diameter stents are used.
Other endoscopic methods like instillation of tissue glue in a small
fistula tract have been reported to achieve some success [4]. However, they
have the disadvantage of occlusion of respiratory tree due to their sealing
9effect. With the widespread use of metal stents, all other modalities have
gone into disfavor. However, there is paucity of evidence and the net
benefit is moderate in terms of morbidity and mortality in the endoscopic
palliative management of malignant AEF.
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Esophageal Metallic Stent Placement
Esophageal self-expanding metallic stent (SEMS) placement is
demonstrated to have maximum therapeutic benefit in patients with TEF
[6]. Stenting is associated with low procedure-related complication of 0–
17% and mortality rate of 0–2%.[11]
Endoscopic placement of SEMS is technically successful in upto 87-
91% of cases and also helps in symptom relief in more than 90% of
cases [13].
Complications
Complications of stent placement in the include perforation when
placed in the cervical regions of the esophagus, stridor due to compression
of major airways and stent migration. Incomplete closure of the fistula
caused by spillage of material through a gap between the proximal stent
margin  and  the  esophageal  wall  can  occur  and  result  in  persistence  of
contamination of respiratory passage. This can be managed by glue
injection to seal the gap or placement of additional stents [14].
Tracheal Stent Placement
The American College of Chest Physicians guidelines for palliative
Care in these patients recommends stent insertion in both the
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tracheobronchial tree and the esophagus for adequate   symptomatic
control [9]. However, the data to support such double stenting is sparse and
few studies have found no additional advantage in terms of symptom
re4lief, morbidity and mortality.
One specific situation in which if stenting in one system (usually the
esophagus first) does not satisfactorily close the fistula, as demonstrated by
dye study during endoscopy or persistence of symptoms, immediately
stenting in the other system is indicated[19].
The site of fistula, extent of disease in the trachea and the amount of
airway compromise determines the need and choice of tracheobronchial
stent. This is best assessed by both bronchoscopy and CT scan of the chest.
Generally, if the fistula tract is 2 cm above the level of carina, a self-
expandable tracheal stenting is done. Also, usage of Montgomery T tube
for similar situation is described as well. If the fistula orifice is at the
carina or within 2 cm of carina, a Y stent is preferred.
Tracheal stenting is performed under general anesthesia using a rigid
or flexible   bronchoscope. The diameter of the prosthesis is based on the
largest scope that can pass into the trachea. The length is determined
according to the principle that it should be 1 cm longer than the fistula for
adequate coverage [20].
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In the event that necessitates dual prosthesis in the esophagus as
well as the trachea, it is generally recommended that airway stenting is
performed first to avoid airway luminal compromise from an expanding
metallic stent in esophagus.
Furthermore, in these situations, it has been demonstrated that
double stenting has better symptom control compared to single
stenting [5].
Stents across GEJ
There may be few patients in this category who need stenting across
the gastro esophageal junction because distal esophageal cancers cannot
fistulise into the tracheobronchial tree as it ends anatomically well above.
Stentingacross the gastro esophageal junction (GEJ) has higher incidence
of migration and gastro esophageal reflux as the lower esophageal
sphincter is lost. Modifications in the make of stents like anti-reflux valve
and partially covered stents are employed in this particular setting [7].
Surgical management of malignant airway-esophageal fistulas
Feeding gastrostomy/jejunostomy is considered to be the ultimate
choice in treating these patients before the era of endoscopic stenting. It
helps in providing nutrition for these patients suffering from dysphagia and
to some extent palliates the respiratory infection. In the present day, its role
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is very limited and even contraindicated. There are certain situations when
stent  is  not  available  or  not  affordable  by  the  patient  during  which  this
option is exercised. One study compared these feeding procedures with
metal stents and found that stenting improves the patients’ quality of life
[10].  In  another  recent  study  by  Choi  et  al  [12],  gastrostomy  was
performed in 20 of 52 patients (38%) of esophageal cancer patients with
esopahgorespiratory fistulas and compared with patients who undergo
stenting. They found that there was no survival difference between the two
groups.
There are reports of surgeries like esophageal exclusion, esophageal
bypass, or fistula resection and repair for palliation of TEF. Esophageal
exclusion included esophagostomy and gastrostomy with closure of the
esophagus above and below the fistula site. Esophageal bypass with
gastric, colonic, or jejuna interposition has been reported by others But
these have very high procedure-related mortality (more than 50%)  as these
are major surgical undertaking in a patient who is very ill and has
advanced malignancy.
In those select few patients who can tolerate the operation these
reports  favor esophageal  bypass as the palliation of  choice with a 30-day
mortality of 25%.They can have a significantly prolonged survival
compared with the supportive care group. Low et al compared the usage of
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esophageal stents versus bypass operation and concluded that stents
achieve satisfactory results with minimum impart on morbidity and low
mortality [17]. It has to be emphasized that in the current era of esophageal
and/or airway stents, the role of the above-mentioned surgical procedures
in extremely limited.
Best Supportive Care
Supportive care includes intravenous fluids/ total parenteral
nutrition, antibiotics for respiratory sepsis, enteral nutritional access by
jejunostomy or gastrostomy or nasogastric tube with or without a
tracheostomy. In a report from Memorial Sloan Kettering Cancer Center,
two groups of patients (n=207) were compared, one receiving specific
therapy for esopahgorespiratory fistulas and the other group receiving only
best supportive care[15]. The arm receiving specific fistula-directed
therapy was found to have significant increase in survival compared to
those in the supportive care arm. This was a report published in 1991 much
before the widespread usage of SEMS.
Radiotherapy for Malignant TEF
Initially, malignant TEF was considered as an absolute
contraindication for radiotherapy for the fear of exacerbation of fistula.
Contrary  to  this  belief,  Yamada  et  al  published  their  experience  in
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radiotherapy for malignant esopahgorespiratory fistulas. In their report of
14 patients, two were long term survivors with one patient surviving more
than 5 years. In 1993, Mayo clinic group reported their experience in using
radiotherapy for 10 patients with malignant TEF and concluded that it can
be safely administered in this group of patients. In their study, 60% of
those patients died of metastatic disease rather than from TEF. Radiation
induced soft-tissue swelling in the region of the fistula can result in either
temporary closure or substantial narrowing, and therefore, decreased
contamination of the respiratory tract.
Follow-up
A close follow-up of patients with esopahgorespiratory fistulas is
mandatory to identify recurrence of symptoms [21]. This may arise due to
non-sealing of a fistula after stent placement or reopening of a fistula after
initial sealing and has the potential to cause sudden death of the patient. It
is always advisable to perform a barium esophagogram immediately after
stenting. It ensures adequate closure of the fistula before starting orals. If
still persistent leak into the airway is noted, oral feeds are withheld and
barium swallow is repeated after 2-3 days. During this time, it is expected
that further expansion of stent can seal off the tract. Also, it is worthwhile
to generate a protocol of periodical barium studies during the follow-up
period for early identification of recurrent aspiration.
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Survival
The survival  figures  are  dismal  even  after  satisfactory  palliation  of
fistula with a median survival ranging from 1 to 6 weeks and less than 5%
1- year survival rate. The most common cause of death in these patients is
pulmonary sepsis rather than the advanced malignancy reiterating the fact
that this is crucial turning-point in the natural history of cancer esophagus.
Acquired Nonmalignant Esophageal Fistulas
The most common causes of acquired nonmalignant esophageal
fistulas are foreign bodies, granulomatous infection like tuberculosis,
cuffed endotracheal tubes and traumatic causes like corrosive injury to the
upper aerodigestive tract and iatrogenic trauma during surgery in the neck
and thorax.
A particular trend was observed in the incidence of TEF related to
endotracheal cuff injury. Until late 1960s, the largest series of acquired
TEF and BEF patients did not contain single case related to endotracheal
cuff trauma [22]. However, quite early in the next decade, a series by
Thomas  had reported 46 such cases[23].
Post Intubation Tracheoesophageal fistulas
A postintubation fistula occurs due to erosion of the membranous
wall of the trachea and the adjacent esophageal wall. The cuff in the
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endotracheal tube exerts pressure on the tracheal wall circumferentially
and on the anterior wall of esophagus which is adherent to the trachea. The
damage is accentuated when there is a nasogastric tube lying in the
esophageal lumen. Many of these patients who were either on prolonged
ventilator support or on long term tracheostomy tube will usually have a
Ryle’s tube in place for feeding. Over inflation of a large-volume cuff by
even a small, added volume of air makes it into a high pressure cuff which
can potentially erode the entire width of the membranous wall. These
fistulas are generally large in size and are termed ‘giant fistulas’. However
these fistulas rarely have mediastinal leak/ sepsis since it progresses over
period of time and does not occur acutely. Spontaneous healing of such
fistulae never occurs and prevention is the best method to treat them.
Usage of low-pressure, large-volume cuffs has reduced the incidence but
still, the potential danger exists with prolonged intubation.
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Clinical presentation
If tracheoesophageal fistula develops when the patient is on
ventilator, sudden increase in secretions is noted coming out of the
endotracheal tube which are esophageal contents. Also, it becomes
increasingly difficult to maintain a seal with the cuff. This event is
followed by appearance of pulmonary infiltrates in the dependent lung
fields which soon becomes a patch of pneumonic consolidation. The
patient eventually lands up in respiratory failure. Upon ventilation, air can
be heard escaping into pharynx and abdomen can become distended as
ventilator air enters the gastrointestinal tract. If the patient is on nasogastric
tube feedings, these material can be seen entering the endotracheal tube.
Chest x-ray reveals pulmonary infiltrates and the esophagusmay
appear  dilated distal to the fistula and the stomach may be filled with air.
A bedside test can be performed by making the patient drink water stained
with methylene blue which will be seen to appear in the tracheostomy.
Nevertheless, aspiration of the swallowed water into the larynx and trachea
can  still  produce  the  same  results.  Hence,  this  test  should  be  carefully
interpreted. In certain cases, the fistula may be visible directly through the
tracheostomy orifice itself.
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Bronchoscopy is the investigation of choice in patients suspected to
have  TEF.  It  can  be  performed  through  the  endotracheal  tube  or  the
tracheostomy tube. The lengths of the fistula and of the normal airway are
measured. A postintubation fistula usually lies a 1-2 cm below the level of
a tracheostomy, since the fistula is located at the cuff site. Upper GI
endoscopy can also be done to visualize the level and extent of the opening
on the esophageal side
Tuberculous Tracheoesophageal fistulas
In fistulae due to granulomatous inflammation like tuberculosis, the
size of the fistula is usually small as the pathology involves only the
membranous portion of trachea[24].
Traumatic fistulae
Traumatic fistulae can be very large as it may be accompanied by
mediastinal sepsis also. There may also be an element of tracheal ischemia
due to surgical dissection in the vicinity [25].Sometimes, expandable metal
stents in trachea and esophagus can erode and cause TEF[26].
Other rare causes
Certain immunodeficiency states can produce necrotizing
esophagitis leading onto tracheo- and bronchoesophageal fistulas with very
high mortality rates [27]. This usually requires esophagectomy.
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Management
Majority of these patients require surgical management. Adequate
control of pulmonary and local sepsis is indispensible for good outcomes.
Hence aggressive preoperative preparation is necessary.
The optimum surgical therapy is individualized based on the
etiology and the patho-anatomy. Most of the fistulas can be approached by
cervical incision. Only supracarinal and bronchoesophageal fistulas need a
thoracotomy. It is usually a right thoracotomy for a tracheoesophageal
fistula and the side of bronchus determines the side of thoracotomy.
 Principles of surgical repair of the TEF were enunciated by Grillo
and colleagues and it includes [30]
a. Complete dissection of the fistula
b. Division of the tract
c. Tension-free Tracheal closure without air leak
d. Two-layered esophageal closure.
It is generally advised to place a vascularized healthy tissue in
between the tracheal closure and esophageal suture line to avoid recurrent
fistulization. Usually strap muscle in the neck or intercostal muscle in the
chest is used for this purpose.
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Postsurgical fistulae are treated with respect to the location and size
of the fistula, the presence or absence of necrosis in the trachea,
mediastinitis, and the severity of symptoms. Treatment usually needs
drainage with conservative management.
 An attempt to close a postintubation fistula in a patient who is still
on ventilator is met with failure in almost all cases. Prolonged ventilation
after tracheal reconstruction results in dehiscence of suture line and
recurrence of fistula. Hence, patients with postintubation TEF are initially
managed conservatively and all the effort is directed towards weaning the
patient from ventilator. After extubation, the patient is planned for
definitive surgical repair.  If a nasogastric tube is present, it is removed.
The tracheostomy cuff is inflated with minimum pressure possible and
sited below the fistula. A ventinggastrostomy is created to avoid aspiration
of gastric contents and a jejunostomy is placed for feeding. The
gastrostomy also helps in keeping the stomach from becoming distended.
 The patient is nursed in head-up position. Aggressive chest
physiotherapy and other measures for pulmonary toileting are liberally
utilized. These aforementioned measures are certainly helpful in most, if
not all patients. Still, a small amount of saliva enters the respiratory
passage which is amenable to tracheal suctioning. Esophageal diversion is
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almost never necessary. Oftentimes, the fistula is located so close to the
cricopharyngeus that exteriorized esophagostomy is impossible.
After weaning, surgical correction involves exposure of the tract,
disconnection of the same,    closure of the esophageal opening in layers,
resection of the circumferentially damaged tracheal segment and its
reconstruction using interrupted vicryl sutures. The transverse tracheal
anastomotic suture line and the vertical esophageal suture line are usually
at different levels, even then, it always safer to use an interposition flap of
viable vascularized tissue, which can be raised without any difficulty.  In
rare situations, tracheal defect may be too long to permit tracheal
reanastomosis, the esophagus is closed nonetheless to eliminate the fistula
and tracheal patency, and function is restored with a permanent T tube.If
laryngotracheal stenosis is present, that is managed in the usual way with
resection of the stenotic segment and reanastamosis. All these procedures
are performed  in a single stage.
Extubation
Early extubation following major tracheal surgery is a debatable
issue. There are reports of routine early extubation and selective early
extubationas well[28,29]. As the chance of reintubation is very high in
certain group of patients with decreased pulmonary function, high-grade
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tracheal stenosis and tracheomalacia, these patients are better extubated
after few days of postoperative ventilation.
Results
Three large series of patients with acquired benign TEF , comprising
a total of 78 cases  was summarized by Dartevelle and Macchiarini [31]. It
showed performance of simple closure of fistula in 29, closure with
tracheal resection in 44, and diversion in only 5 patients. Recurrences of
TEF  were  at  the  rate  of  6.4  to  8.3%  and  mortality  was  between  6.3
and12.5% .The authors commented that definitive single stage repair is
clearly superior over other types of surgical repairs of varying complexity
Late presentation of Boerhaave’s syndrome –
Esophagopleurocutaneous fistula
Esophageal barotrauma or Boerhaave’s syndrome can have acute,
sub-acute, and chronic presentation. Acute perforation presents with
symptoms within twenty-four hours after rupture [32]. In sub-
acuteperforation, symptoms develop between twenty four hours to two
weeks following perforation. With chronic perforation, the onset of
symptoms is more insidious, often delaying presentation and diagnosis for
weeks to months after rupture. Often   this group of patients has ICD tube
inserted usually on the left side which will be found to drain ingested food
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when the patients resumes oral intake. These patients are managed
conservatively until the sepsis in the pleural cavity resolves. Oral feeds are
eliminated and enteral nutrition through a nasojejunal tube is instituted.
Once the patient recovers, which usually takes 4-6 weeks, they are taken
up for surgical management. A left or right thoracotomy is done depending
on the site of perforation. Usually the perforation is too large to allow
primary closure and hence that segment of esophagus bearing the
perforation is resected and gastrointestinal continuity is established by
esophagogastric anastomosis [33].
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MATERIALS AND METHODS
All patients diagnosed with esophageal fistulas during the study
period from August 2010 to February 2013 were included in the study. The
patients’ demographic data including Name, Age, Sex, place of origin and
occupation were documented. An accurate history taking was done and
recorded systematically. They were examined in detail and findings
tabulated. Each patient’s clinical course was closely monitored and
recorded. The etiology of the fistula, the investigative modalities
undergone by the patient and treatment offered to each patient was noted.
As part of the study, no special treatment was offered to the patient. Each
patient’s natural course in the hospital is observed and analyzed.
In general, patients with malignant tracheoesophageal fistula were
taken up for endoscopic esophageal stent placement. Before stent
placement, the site of the tracheoesophageal fistula (TEF) was assessed by
upper gastrointestinal endoscopy which is performed with topical lidocaine
spray. A guide wire was inserted through the endoscope and  under
fluoroscopic guidance, it is passed distal to the tumor and the site of the
fistula and a covered metallic stent was placed. In the event of
unavailability of stents, they were offered other treatment.
For patients with acquired nonmalignant fistulas, each patient was
individually assessed and treatment decisions taken by multidisciplinary
team.
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RESULTS
A total of 46 patients with esophageal fistula were included in the
study.  Among  the  46  patients,  there  were  31  patients  who  had
tracheoesophageal fistula due to malignancy and the other 15 patients were
due to non-malignant etiologies.
We have classified the esophageal fistula patients we have
encountered into three types, viz, External, Internal and Interno-external
types depending on whether the esophagus communicates with cutaneous
surface, with tracheobronchial tree or external communication through the
pleural cavity. The classification system and number of cases we have seen
in each category is illustrated in the figure below.
Malignant
67%
Non-
malignant
33%
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Malignant Tracheoesophageal fistula
The cause of malignant tracheoesophageal fistula was carcinoma
esophagus in all 31 cases. Of note, we have not encountered any cases of
bronchogenic carcinoma or tracheal malignancy resulting in malignancy.
All esophageal cancer patients were histopathologically squamous cell
carcinomas. None of the 31 patients were diagnosed with esophageal
adenocarcinoma,
28
ETIOLOGY(All tabulations in this manuscript has number of patients
in the right column)
Carcinoma esophagus 31
Bronchogenic carcinoma 0
Tracheal neoplasm 0
Mediastinal lymphoma 0
Others 0
Among patients with carcinoma esophagus who developed
fistulisation into the airway, 18 patients had received no treatment
previously and their mode of presentation was dysphagia for a short period
with new onset cough, especially after water intake. However, 13 patients
had been diagnosed with malignancy and had taken some form of
treatment including chemotherapy, radiotherapy or both.
PREVIOUS THERAPY
None 18
Radiotherapy only 5
Chemotherapy only 3
Both chemo and radiotherapy 5
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EXAMINATION
Performance Status
1-2
3-4
12
19
Nutritional status
Good
Moderate
Poor
3
8
20
Pallor 21
Pedal Edema 5
Supraclavicular lymphadenopathy 7
The performance status of patients as assessed by ECOG score
(European Cooperative Oncology Group score) were good (1-2) in 12
patients. However, a significant number of patients (19/31) were having
poor performance status: confined to bed majority of the time and not able
to carry our activities of daily living without help.
Nutritionally, 20 of 31 patients were poor and only 11/31 patients
were  well-nourished or moderately nourished. One third of patients
(21/31) were pale clinically and 5 patients had bilateral pitting pedal
edema. Seven of 31 patients had supraclavicular lymphadenopathy, mostly
in the left side.
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All the patients were subjected to upper gastrointestinal endoscopy.
The location of  fistula was in the middle third of  esophagus in almost  all
patients (22/31 patients). In the remaining 9 cases, the exact location of
fistula was not made out as the growth was occupying the entire lumen not
admitting the passage of endoscope. In patients in whom the fistula site
was visualized, it was less than 1 cm in 12 patients and large (> 1cm) in 3
patients. However, due to the presence of stenosing ulceroproliferative
growth, the size of the fistula was not assessed in 16 cases.
Endoscopic biopsy was done in 18/ 31 cases and proven to be
squamous cell carcinomas, while the other 11 patients had biopsy-proven
disease already.
FINDINGS ON UGIE
Site of fistula
Upper third
Middle third
Lower third
Not identifiable
0
26
0
5
Size of the fistula
<1cm
>1cm
Not assessed
12
3
16
Growth Negotiable 22
Biopsy if any 24
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RESPIRATORY SYSTEM
Aspiration
Right
Left
10
2
Pneumonia - consolidation 7
Lung abscess 2
Pleural effusion 1
Lung metastasis 4
As respiratory system is most commonly affected by the presence of
airway-esophageal fistula, we tended to document the findings on chest
roentgenogram more diligently. We found features of aspiration
pneumonia (fleeting infiltrates in the dependent portions of the lung fields,
namely the superior segments of the lower lobes and posterior segments of
the upper lobe, usually on the right side due to straighter course of the
bronchus) in 12/31 cases.  Also, features of consolidation were found in 7
patients. In two patients, a well-defined lung abscess cavity with air-fluid
level was seen tracking down from the fistula orifice. In 4 out of 31 cases,
there were coin lesions in both lung fields, suggesting metastasis.
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BRONCHOSCOPIC FINDINGS
Respiratory location of the fistula
Above Carina
Below Carina
Not known
18
6
4
Growth seen at the level of fistula 18
Size of the fistula
<1cm
>1cm
19
4
Twenty eight out of 31 were subjected to fiber-optic bronchoscopy.
The other 3 patients were too sick to be shifted to bronchoscopy room.
Among them, the opening of the fistula in the airway tract was above the
carina in 18 patients and in the right or left bronchus in 6 patients. During
the procedure, the site of fistula could not be definitely assessed in 4
patients due to pooling-up of large quantity of esophageal secretions or
patient’s intolerance during the study. In 18 patients, growth was seen at
the fistula, a few with associated bullous edema. However, no attempt at
biopsy was done, as many of them had proven malignancy. The size of the
fistula was small (<1 cm) in 19 patients and larger than 1 cm in 4 patients.
33
TREATMENT OFFERED
Esophageal metallic stent 14
Airway stenting 0
Feeding gastrostomy 1
Feeding jejunostomy 7
Best supportive care 3
Surgery 0
Radiotherapy 4
Chemotherapy 2
The treatment offered was esophageal stenting using self-expanding
metal stent (SEMS) in 14 patients. In 8 patients, feeding procedure in the
form of gastrostomy or jejunostomy was done. Three patients were too
sick for any form of treatment and hence were advised best supportive care
which included iv fluids, head end elevation, respiratory physiotherapy,
bronchodilators and antibiotics. Four patients in whom fistula was small
and the lung sepsis was minimal, radiotherapy was offered primarily and
two similar patients received chemotherapy only. Of note, none were
offered surgery for malignant tracheoesophageal fistula in the form of
resection or bypass or exclusion procedures.
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CLINICAL OUTCOMES IN PATIENTS UNDERGOING ENDOSCOPIC
STENTING
Technical success 86%
Clinical Success 94%
Mean dysphagia score before stenting 3.4
Mean dysphagia score after stenting 1.8
Among patients undergoing esophageal stenting, the technical
success rate was 86% (all but one patient could be successfully stented in
one or two attempts). A majority of patients (94%) had clinical relief of
dysphagia suggested by improvement in the dysphagia scores before and
after stenting from 3.4 to 1.8.
STENT PLACEMENT – PROCEDURE RELATED COMPLICATIONS
Pain 2
Perforation 0
Bleeding 1
Aspiration 4
Migration 2
A few patients had complications related to placement of esophageal
SEMS. Two out of 14 patients had chest pain following the procedure. No
cases of perforation were documented. One patient had mild bleeding from
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the tumor during the expansion of the stent which settled spontaneously.
Four patients had exacerbation of respiratory signs in the immediate post-
procedural period with their chest roentgenograms showing infiltrates
suggestive of aspiration. Two patients had distal migration of stent and it
was found lying free in the stomach. No specific therapy was done for the
same and they were conservatively managed.
TREATMENT AFTER STENTING
Chemotherapy 2
Radiotherapy 1
Both 5
Best supportive care 5
Following stenting, 8 out of 14 patients were further sent for
chemotherapy, radiotherapy or both. Five patients were too ill to undergo
any specific therapy and were offered only supportive care.
CAUSE OF DEATH
Pulmonary sepsis 4
Bleeding 0
cachexia 1
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Among 31 patients with malignant esopahgorespiratory fistulas, we
had encountered 5 in-hospital deaths, four of them were due to
uncontrollable pulmonary sepsis and the other patient died of cancer-
related cachexia.
FOLLOW –UP
Improvement in dysphagia 13
Control of respiratory infection 4
Upon follow-up, we could note a sustained improvement of
dysphagia in 13 patients and good control of respiratory infection in 4
patients.
Non-malignant Esophageal fistulas
We had 15 patients with non-malignant esophageal fistulas. The
most common etiologies were foreign body ingestion and delayed
presentation of Boerhaave’s syndrome in the form of
esophagopleurocutaneous fistula. Other less common etiologies were listed
in the table given below.
Foreign body ingestion 4
Post-Intubation 2
Spontaneous 1
Iatrogenic 2
Corrosive ingestion 2
Boerhaave’s syndrome 3
Tuberculosis 1
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DEMOGRAPHICS
The age distribution of cases of esophageal fistulas in each age
group was shown. Of particular mention, patients with foreign body
0
2
4
No of patients
No of patients
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ingestion and post-intubation TEF were in the 2nd and 3rd decade of life and
patients with Boerhaave’s syndrome were in 5th and 6th decade of life.
There  is  almost  equal  distribution  of  cases  gender-wise  with  53%
males and 47% females.
SYMPTOMATOLOGY
male
53%
female
47%
No. of patients
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A majority of patients had the typical swallow-induced cough (12
out of 15 cases), the so-called Ono’s sign. Eight patients had complained
of coughing of ingested food. Four patients had chest pain. Two patients
had dyspnea and hemoptysis. Four patients had reported history of foreign
body ingestion and two patients had suicidal ingestion of corrosive liquid
(toilet cleaning acid).
CLINICAL EXAMINATION FINDINGS
Built and nourishment
Mild- Moderate
Poor
10
5
Performance status
1-2
3-4
12
3
Pallor 3
Pedal edema 1
Tracheostomy 3
Feeding tube in abdomen 4
ICD tube 3
On  examination,  5  out  of  15  patients  were  poorly  nourished  and
among them 3 patients were in poor performance status (ECOG scores 3-
4). In this group of patients, 3 had tracheostomy tube in situ, 4 had feeding
tubes and 3 patients had intercostal drainage tubes in place.
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PULMONARY PROBLEMS
Aspiration pneumonia 8
Lung abscess 1
Pulmonary tuberculosis 1
asthma 1
COPD 3
Pleural effusion 3
Consolidation 2
Sudden aspiration and death 1
Respiratory system had the maximum impact due to the presence of
fistula with features of aspiration pneumonia seen in 8 of 15 patients. One
patient  had a abscess cavity. In one patient, the fistula was due to
pulmonary tuberculosis. Three patients with delayed presentation of
Boerhaave’s syndrome had pleural effusion with ICD tube draining it. One
patient had succumbed to sudden aspiration of acidic gastric contents
(Mendelson syndrome). He was intubated instantly and connected to
mechanical ventilator support but could not be salvaged.
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WHICH INVESTIGATION ESTABLISHED THE DIAGNOSIS
Barium swallow 5
Upper GI endoscopy 2
Bronchoscopy 2
Gastrograffin swallow 1
CT Chest 5
We made an analysis of which particular upper aerodigestive
investigative modality established the diagnosis and found that in most of
the patients (10 out of 15 patients) imaging in the form of barium
esophagogram or contrast enhanced computed tomography (CECT) of the
neck and thorax pinned down the diagnosis. Upper GI endoscopy and
Bronchoscopy were employed for the diagnosis in 4 patients.
DIAGNOSIS PLACE
Our department 7
Other department 4
Outside hospital 4
Another observation we liked to analyses was the place of diagnosis
of the esopahgorespiratory fistula. Seven out of 15 patients were diagnosed
in our department and 4 patients each were either  diagnosed in other
departments in our hospital or referred with the diagnosis from outside
hospitals.
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FINDINGS ON CHEST X RAY
Visualized foreign body 2
consolidation 6
Pleural effusion 4
Calcified lymphnodes 1
The findings on chest X-rays were recorded among these patients
and 6 out of 15 patients had consolidation. Two patients had foreign body
visualized  on  the  CXR  film.  Of  particular  note,  two  other  patients  with
foreign body ingestion did not have a radiopaque shadow on the chest film.
Four  patients  had  pleural  effusion  and  the  patient  with  tuberculous  TEF
had calcified hilar lymph nodes.
UPPER GI SCOPY FINDINGS
Level of opening
Upper third
Middle third
Lower third
7
5
3
Size of the fistula opening
<1cm
>1cm
9
6
Air escaping through tracheostomy
on insufflation
4
Corrosive induced changes 2
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All patients were subjected to upper gastrointestinal endoscopy in
our department. The site of fistulous opening was in the upper third of the
esophagus in 7 of 15 patients and middle third in 5 patients. In those
patients with delayed presentation of barotrauma, the fistulous opening
was seen in the distal third of esophagus. The size of the opening was less
than 1 cm in 9 patients and more than 1 cm in 6 patients. In those patients
who had tracheostomy in place, we could observe air that was insufflated
on endoscopy escaping through the stoma. In patients with corrosive
induced tracheoesophageal fistula, the esophageal mucosal cicatrices were
observed.
BRONCHOSCOPIC FINDINGS
Granulation tissue 3
Visualization of fistula orifice 8
ulceration 2
Endobronchial mass 1
Luminal narrowing 3
Site of fistula on tracheobronchial side
Trachea
bronchus
7
2
Similarly, all of our non-malignant airway-esophageal fistula
patients underwent fibreoptic bronchoscopy. Among 15 patients, fistula
orifice was observed in 8 patients. The site of fistula was in the trachea in 7
44
patients and in the bronchus in 2 patients. In those patients who had
trachea-esophageal fistula following prolonged intubation, there was
associated stenosis of tracheal lumen, especially in the subglottic region.
BARIUM SWALLOW FINDINGS
Foreign body 3
Esophageal stricture (corrosive) 2
Aspiration into tracheobronchial tree 3
Abscess cavities in lung 1
Barium swallows revealed foreign body in 3 patients. Esophageal
stricture was seen in patients who had corrosive ingestion. Three patients
showed aspiration into the tracheobronchial tree with abscess cavity in
lung in a single patient.
FINDINGS ON CT IMAGING
Thickening of esophageal wall 6
Hilar lymphadenopathy 1
Fistula 7
Pleural effusion 5
Mediastinal collection 2
Lung consolidation 6
bronchiecctasis 2
bronchiolith 0
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APPROACHES
Cervical  incision 6
Sternotomy 0
Right thoracotomy 4
Left thorocotomy 1
Eleven patients out of 15 cases of non-malignant fistulas were
treated surgically by various procedures. The approach to the fistula site
was dictated by the level of opening on the esophageal and tracheal side.
Overall, 6 patients had cervical approach, 4 patients had right thoracotomy
and one patient had left thoracotomy approach. Of note, none of the
patients had a sternotomy or abdominal exploration.
SURGERY
Excision of the tract 3
Interposition of vascularized tissue 2
Closure of the esophagus 2
Excision of trachea 2
Laryngeal resection 0
Laryngeal release 1
Tracheal anastomosis 1
Difficulty in exposure of the fistula 1
Need for tracheostomy 2
Esophagogastric anastomosis 3
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The specific surgical procedure carried out was also a recorded. The
tract was excised in three patients and sent for histopathology. The
esophageal defect was closed in single or two layers using 3-0 or 4-0
polyglactin 910 (vicryl). The tracheal surgery was individualized. Tracheal
resection  was  done  in  2  patients  who  had  subglottic  stenosis  due  to
endotracheal or tracheostomy cuff induced pressure necrosis. Tracheal
anastomosis was done in interrupted fashion using 3-0 vicryl. For reducing
tension at the tracheal anastomosis, laryngeal release was performed in one
patient who had excision of 3 rings. After closure of  both the tracheal and
esophageal defects, vascularized tissue  was interposed between the two. In
the neck, strap muscle was used and in the chest, pericardium was used.
For patients with Boerhaave’s syndrome, resection of the esophagus
containing the fistula site was done (i.e the lower third esophagus) with
gastric tabularization and esophago-gastric anastomosis in chest. This was
done using circular EEA stapler  25 mm (Ethicon, MA).
EXTUBATION AT THE END OF SURGERY
Immediate 6
Early 2
Delayed 3
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OTHER PROCEDURES DURING SURGERY
Cervical esophagostomy 1
Gastrostomy 1
jejunostomy 6
ICD tube insertion 5
In one patient with foreign body impacted in the cervical esophagus,
it was removed and a lateral cervical esophagostomy was done. Feeding
procedure in the form of jejunostomy or gastrostomy was done in seven
patients.
POSTOPERATIVE PERIOD
Failure of tracheal repair 2
Failure of esophageal repair 3
Aspiration pneumonia 4
Respiratory failure 1
Abdominal distension 1
chylothorax 0
Need for reintubation 1
Need for ICD insertion 1
Many patients who underwent surgical management of non-
malignant esophageal fistulas had an eventful postoperative period. In two
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patients who had tracheal repair, dehiscence with air leak was observed in
the immediate postoperative period. Both patients were taken up for
revision in the emergency operation theatre and tracheostomy was
performed. Three patients had a trivial leak from the esophageal closure
site resulting in cervical salivary fistula which settled with conservative
management. Four patients had recurrent aspiration pneumonia
progressing onto respiratory failure and necessitating endotracheal
intubation. One patient had abdominal distension, possibly due to
aerophagy or paralytic ileus. One patient developed pleural effusion which
mandated insertion of thorocostomy tube.
MORTALITY CAUSES
Mediastinal sepsis 1
Tracheal dehiscence 1
Aspiration 1
There were three deaths among the non-malignant fistula group. One
patient had tracheal dehiscence with respiratory failure. One patient with
corrosive induced tracheoesophageal fistula had recurrent lower respiratory
infection and succumbed to the same. Another patient died of mediastinal
sepsis.
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LENGTH OF HOSPITAL STAY
Median length of stay in hospital in
preoperative period
12.7 days ( range 8 to 76 days)
Median length of stay in ICU 4.1 days
Median length of stay in hospital in
postoperative period
16.2days
Median length of stay in hospital
(total)
33.8 days
FOLLOW-UP
Recurrent TEF 1
Reoperation for TEF 0
Still on tracheostomy 1
Euphagic 7
Patients were followed up for a period of 7.1 months (range, 2 to 21
months). One patient had recurrent TEF and still on follow-up. Another
patient who had tracheal anastomotic dehiscence was still on
tracheostomy. Seven patients were euphagic and having normal respiratory
function.
FOREIGN BODY INDUCED BRONCHOESOPHAGEAL FISTULA
CT Chest and Bronchogram – Showing left BEF
Endoscopic view showing opening in esophagus
Intraoperative – encircled esophagus; removed denture
TUBERCULOUS TRACHEOESOPHAGEAL FISTULA
Barium swallow and UGI Scopy showing the fistula
Repair of esophagus
Pleural Patch between esophagus and trachea
MALIGNANT TEF – ENDOSCOPIC STENTING
(also shows an abscess cavity in the right lower lung zone)
Endoscopic view of guidewire and  SEMS
POSTINTUBATION TEF (2 patients)
CT AND ENDOSCOPIC VIEW (Note: tracheostomy tube in situ)
      INCISION          FISTULA OPENING SEEN THROUGH THE TRACHEA
REPAIR OF ESOPHAGUS AND TRACHEA
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DISCUSSION
Esophageal fistulas are complex clinical problems encountered
predominately in tertiary care centers. In our hospital, we encountered a
total of 46 cases with airway-esophageal fistulas. Among them two-thirds
were due to malignancy and one-third are acquired non-malignant causes.
This is true even in Western literature as we can observe a majority of
cases are due to malignancy. However, acquired causes are important
treatable but clinically challenging situations requiring multidisciplinary
team management.
Among the various cancers that can potentially cause airway-
esophageal fistula, our records show only esophageal malignancy related
fistulas  in  this  group.  This  is  probably  attributed  to  the  fact  that,  our
department of surgical gastroenterology gets highly selected reference
cases. Also, we have other departments of cardiothoracic surgery and
medical oncology which admits cases of TEF due to other malignancies.
These patients were not included in our study.
After accumulation of cases for our study, we embarked on a
classification system for the group of patients we had analyzed. In our
study, esophageal fistulas were classified into internal, external and
interno-external. The ‘internal’ group comprises of fistulas between
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esophagus and airway (either trachea or bronchi). The ‘external ‘group
consists of esophagocutaneous fistulas. And the interno-external type
results from delayed presentation of esophageal barotrauma (Boerhaave’s
syndrome) .In such situations, ICD tube is placed for pleural effusion and
it starts to drain ingested material, thereby establishing an
esophagopleurocutaneous fistula.As found in our study, the ‘Internal’ type
consisted of both malignant and non-malignant fistulas, whereas the other
two types were only acquired benign causes.
Among the patients with malignant TEF, 55% presented with fistula
at the time of primary diagnosis. However, 45% patients had fistulisation
following radiotherapy or chemotherapy or both. It is established in the
literature that chemo radiotherapy for cancer esophagus can result in TEF,
especially in locally advanced cases with tracheobronchial tree invasion.
One third of patients with malignant TEF was cachectic and had
poor performance status. Also 22% patients had supraclavicular
lymphadenopathy and hence, stage IV disease.
Because of the proximity of middle third esophagus to trachea, 83%
of cases had the level of fistula in the midthoracic esophagus. We did not
see any patient with cervical esophageal cancer fistulising into larynx or
trachea. In the remaining 17% cases, the stricture’s growth was not
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permitting passage of endoscope to assess the level of fistula. However, we
presume that it should be in mid thoracic esophagus.
The trickle of esophageal contents into the airway is a constant
source of pulmonary sepsis as evidenced by our study that 61% cases had
either signs of aspiration or pneumonia. We could also note lung
metastasis in 4 out of 31 cases (12.8%). Considering supraclavicular node
and lung metastasis, overall one third of patients with malignant TEF had
stage IV disease.
The location of fistula in the airway was bronchial in 19.3% cases
and  the remaining were supracarinal fistulas. Especially, one patient with
right bronchoesophageal fistula had adjoining abscess cavity.
The treatment offered for these patients was esophageal SEMS in
45%, feeding gastrostomy/ jejunostomy in 25% cases, radiotherapy +/-
chemotherapy in 19% cases and the rest were offered best supportive care.
The deployment of esophageal stent was technically successful in all
but one patient in whom guide wire could not be passed across the
stricture. In 94% of cases, the stent was clinically successful with
improvement of dysphagia and control of respiratory infection. The
complication rate with stenting was minimal with no perforation and 2
cases of distal migration. However, the patients’ tolerability of the
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procedure was observed to be good. Of note, two-thirds of patients were
sent for furtherradio chemotherapy following stenting.
The in-hospital mortality rate was 16% among malignant TEF
patients with majority of death occurring due to pulmonary sepsis. All
patients were followed up for a mean duration of 6.1 months, (range, 2 to
10.2 months) and among those patients who underwent stenting, sustained
improvement in dysphagia and respiratory infection was observed.
However, four patients (13%) died within 6 months of stenting.
Acquired Non-malignant Esophageal fistulas
In our series, 33% of cases were due to acquired non- malignant
causes. The most common cause is foreign body ingestion (27%) closely
followed by Boerhaave syndrome (20%). Other causes include post-
intubation TEF, corrosive e ingestion and post-surgical (13% each). Rarely
we did encounter a patient with tuberculous TEF and another patient had a
spontaneous TEF without any obvious etiology.
Contrary to malignant TEFs with occurs in 6th or 7th decades of life,
these acquired benign cases occur predominantly in patients less than 50
years old. Of note, all the patients with delayed presentation of Boerhaave
syndrome were more than 50 years old and chronic alcoholics.
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Unlike malignant TEF patients who were ill-nourished and had poor
performance status, the patients with benign fistulas were moderately
nourished, but had good performance status. As expected, almost all
patients had abnormal respiratory system findings and one out of 15
patients died due to sudden massive aspiration of acidic gastric contents
(Mendelson syndrome).
We made a special analysis to determine which particular
investigation helped in confirmation of diagnosis. We found that in two
thirds of patients, imaging study in the form of thin barium swallow of CT
scan was fruitful in clinching the diagnosis. Endoscopic studies were not
especially helpful for establishing the diagnosis; rather it is used to assess
the level and extent of fistula and to look for underlying disease of
esophagus or trachea.
Another factor we took into consideration was the place of
diagnosis. We observed that equal number of cases was diagnosed in our
department and outside our department. This brings into picture the pattern
of references we get and usually all those were delayed referrals. This adds
to the complexity of diagnosis and management. Those patients diagnosed
in our department benefit from early institution of appropriate therapy.
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In fistulas arising due to foreign body ingestion, only two foreign
bodies were seen on chest roentgenogram. The other two were radiolucent
foreign bodies (1 denture and 1duck bone). In upper GI endoscopy, only
esopahgopleural fistulas were in the distal esophagus, other cases involved
either upper of middle third esophagus. There were two
bronchoesophageal fistulas and 7 tracheoesophageal fistulas.
In this group, 60% cases were managed by surgical intervention and
the remaining patients were treated conservatively. Cervical incision along
the anterior border of left sternocleidomastoid was employed for 6 cases
while other patients underwent thoracotomy. Thoracotomy was performed
in the right side for all but one patient who had a left bronchoesophageal
fistula due to retained foreign body.
Surgery was done with adherence to all the principles of surgery of
TEF as outlined by Grillo et al. In patients with postintubation TEF, the
tract is dissected; disconnected and esophageal closure was done in two
layers. As one of the patients had coexisting subglottic stenosis, resection
of tracheal segment consisting two rings was done and end-to-end
anastomosis was done with 3-0 vicryl in interrupted fashion.  In the other
patient with postintubation TEF, after closure of the esophagus, the defect
in trachea was too large to achieve satisfactory primary closure. So, it was
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converted into a tracheostomy. In the second stage, two months following
the  first  surgery,  tracheal  closure  was  performed.  In  those  patients  with
distal esophageal fistula resulting from delayed presentation of
Boerhaave’s syndrome, the distal esophagus containing the fistula site was
resected and esopahgogastric anastomosis was done intrathoracically.
Adjunctive procedures like feeding jejunostomy/ gastrostomy and
intercostal drainage tube insertion were utilized as the situation mandated.
Extubation  at  the  end  of  surgery  was  possible  in  40%  cases,  in  the
remaining our anesthetist decided to extubate the patient after a period of
postoperative ventilation. This however did not have an impact on the
dehiscence of tracheal suture line in our patients.
The operative results in this group were satisfactory with all patients
operated for Boerhaave’s syndrome doing very well at the end of 1 year
follow-up. The two patients operated for postintubation TEF had good
recovery and feeding orally, but one patient is still on tracheostomy. One
patient with retained foreign body- related bronchoesophageal fistula, after
removal  of  the  denture,  esophageal  and  bronchial  end  was  closed.  The
patient recovered and was discharged. A month later, he was admitted in
our ward for aspiration due to alcohol intoxication and died of respiratory
failure. The sole patient with tuberculous TEF, the fistula persisted despite
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completion of anti-tuberculous therapy and she was managed surgically by
right thoracotomy, disconnection of the tract and closure of both the
passages. She is leading a normal life when she was seen in our out-patient
clinic two years after the surgery.
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CONCLUSION
In conclusion, we would like to state that esophageal fistulas are
complex and heterogeneous disorders. The mode of clinical presentation
varies depending on the etiology.
With respect to malignant tracheoesophageal fistulas, stenting of the
esophagus and/or the airway is  the current  standard of  care.  If  the patient
presents late in the course of the fistula with pulmonary sepsis, he shall be
best managed with supportive care and no heroic measures should be tried.
Surgical management of malignant TEF finds very little place in the
modern endoscopic stenting era.
With regards to acquired non-malignant esopahgorespiratory
fistulas,  majority of  them are managed surgically with strict  adherence to
well-established principles of operative management.  With careful
preoperative preparation and diligent postoperative care, results are
extremely satisfactory.
We would like to emphasize that these disorders are best managed in
tertiary care hospitals where multidisciplinary team management is
possible and helps in achieving the best possible results.
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PROFORMA
Name-
Age-
Sex-
IP No:
Address-
Phone Number:
Education status (in years)-
Occupation (level)-
H/o difficulty in swallowing
H/o swallow induced cough
H/o cough with expectoration
H/o difficulty in breathing
H/o foreign body ingestion
Day of ingestion
Day of surgery
Day when leak appeared
Day when stopped
Consumption of acid/alkali
Intention for consumption
H/o prolonged intubation
H/o tracheostomy
Day of leak
H/o fever
H/o loss of appetite
H/o loss of weight
H/o chemotherapy/ radiotherapy
H/o alcohol intake- amount,frequency
H/o smoking
H/o DM,SHT,BA,TB
Examination
General examination
Examination of oral cavity
Local examination
Respiratory system examination
Cardiovascular system examination
Abdominal examination
Investigations
Complete blood count
Serum electrolytes
Renal function test
Liver function test
X ray chest
USG abdomen
Upper gastro intestinal scopy
Barium swallow
Contrast Upper GI series
CECT Neck
CECT Chest and Abdomen
Bronchoscopy
Treatment
Type of Surgical Procedure
Type of Endoscopic procedure
Outcome
In hospital stay
Morbidity
In hospital mortality
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1 ramu 50 m 100112 CA ESOPHAGUS N 1 good y y mid third < 1 cm y above carina stent 14
2 thulasiraman 62 m 2250 CA ESOPHAGUS RT 2 good y n mid third not assessed y below carina fg 13
3 ramachandran 32 m 5411 CA ESOPHAGUS N 3 moderate y y mid third > 1 cm y above carina fj 4
4 dharmaraj 22 m 44134 esophagopleurocutaneous fistula ICD 1 good n n mid third < 1 cm y not relevant surgery 57
5 deenadayalan 35 m 57654 FB esophagus N 1 poor y n not assessed > 1cm y below carina surgery 21
6 rengaraj 66 m 69177 CA ESOPHAGUS RT 3 poor y n mid third < 1 cm y above carina stent 8
7 manikkam 63 m 89952 CA ESOPHAGUS CT 4 poor y y mid third < 1 cm y above carina bsc 2
8 narayanan 79 m 97287 CA ESOPHAGUS RT 2 good n n mid third < 1 cm y above carina fj 21
9 doss 38 m 10260 CA ESOPHAGUS N 1 good y n mid third not assessed y above carina stent 15
10 parasuram 40 m 10698 CA ESOPHAGUS N 2 moderate y n mid third < 1 cm y above carina stent 8
11 bitchal 57 m 15352 FB esophagus N 1 good y n upper third not assessed y cervical trachea 27
12 karunakaran 60 m 32390 CA ESOPHAGUS N 1 good y n mid third < 1 cm n above carina stent 12
13 saravanan 20 m 34691 spontaneous fistula N 1 good y n upper third < 1 cm y cervical trachea conservative 25
14 muthusamy 55 m 44372 CA ESOPHAGUS N 1 moderate y n not assessed < 1 cm y above carina ct 12
15 jayapal 42 m 45668 CA ESOPHAGUS CT 4 moderate n n mid third not assessed y above carina rt 11
16 arumugam 70 m 54753 CA ESOPHAGUS N 3 poor y n not assessed < 1 cm y above carina bsc 4
17 bakyanathan 60 m 54762 CA ESOPHAGUS N 3 moderate y n mid third < 1 cm y above carina ct 7
18 babu 43 m 98721 esophagopleurocutaneous fistula ICD 1 moderate y n lower third > 1 cm y not relevant surgery 49
19 ramasamy 70 m 58543 CA ESOPHAGUS N 3 good n n not assessed not assessed y above carina stent 21
20 ramanathan 63 m 74233 CA ESOPHAGUS RT 1 good y n mid third < 1 cm y above carina stent 12
21 subramani 70 m 81632 CA ESOPHAGUS N 1 good n n not assessed not assessed y above carina ct 14
22 saravanan 32 m 25432 post surgical pharyngocutaneous fistulaORTHO 1 moderate y n upper third not assessed y cervical trachea conservative 17
23 perumal 55 m 110028 CA ESOPHAGUS CT 2 good n y not assessed < 1 cm y above carina stent 12
24 ganesan 48 m 116469 CA ESOPHAGUS CRT 3 moderate y n mid third not assessed y below carina stent 6
25 krishnamurthy 54 m 41313 CA ESOPHAGUS N 4 poor y n mid third < 1 cm y above carina bsc 3
26 sampath 56 m 11290 esophagopleurocutaneous fistula ICD 1 moderate n n lower third > 1cm y not relevant surgery 42
27 kasi 62 m 65278 CA ESOPHAGUS CRT 1 good y n mid third < 1 cm y above carina fj 11
28 ponnusamy 65 m 85448 CA ESOPHAGUS CRT 3 good n n mid third < 1 cm n above carina stent 12
29 padmavathy 70 f 15788 CA ESOPHAGUS N 2 moderate y y mid third < 1 cm y above carina fj 16
30 jayagomathi 48 f 22769 CA ESOPHAGUS N 3 moderate y n mid third not assessed y above carina stent 15
31 indrani 55 f 28198 CA ESOPHAGUS N 4 poor n n mid third not assessed y above carina bsc 6
32 prema 45 f 52336 FB esophagus N 1 poor y n mid third < 1 cm y above carina surgery 9
33 ammapillai 51 f 69834 CA ESOPHAGUS N 2 good y n mid third < 1 cm y above carina stent 18
34 jegadeeswari 35 f 5595 CA ESOPHAGUS N 1 good n n mid third < 1 cm y above carina fj 12
35 kasthuri 60 f 12541 CA ESOPHAGUS N 2 good y y mid third < 1 cm n above carina fj 16
36 kalyani 54 f 18155 corrosive esophageal perforation N 3 poor n n mid third < 1 cm y above carina conservative 32
37 selvi 38 f 52635 TB TEF ATT 1 good y n mid third > 1 cm y above carina surgery 41
38 rasia beevi 50 f 50479 CA ESOPHAGUS N 3 moderate y n mid third not assessed y below carina fj 12
39 sundarammal 39 f 81647 CA ESOPHAGUS N 4 good n y mid third < 1 cm y above carina stent 13
40 senthakkal 70 f 6357 CA ESOPHAGUS N 4 good y n mid third not assessed n above carina stent 8
41 krishnaveni 23 f 29140 post-intubation TEF N 1 moderate n n upper third < 1 cm y cervical trachea surgery 61
42 saraswathi 38 f 41382 FB esophagus N 1 moderate y n mid third not assessed y above carina surgery 32
43 vendamani 43 f 52783 post-intubation TEF N 1 moderate n n upper third > 1cm y cervical trachea surgery 8
44 fathima 30 f 59844 CA ESOPHAGUS N 4 good y n mid third not assessed y above carina bsc 76
45 gunalan 55 m 3451 post-laryngectomy LRYX 1 good y n upper third > 1 cm y cervical trachea conservative 12
46 devamalar 42 f 15231 corrosive esophageal perforation N 3 poor y n mid third not assessed y above carina conservative 31
MASTER CHART
INFORMED CONSENT FORM
Title of the study -
Study of Presentation, Management and outcome of Esophageal Fistulas
Name of the participant: ____________________________________________
Name of the Principal/Co-Investigator: Madhusudhanan J_________________________________
Name of the Institution: _____Madras Medical College and Rajiv Gandhi Government General
Hospital, Chennai - 03________________________________________
Name and address of the sponsor / agency(ies), if any: __None___________________
I,________(name of participant), have read the information in this form (or it has been read to me). I
was
free to ask any questions and they have been answered. I am over 18 years of age and, exercising
my free power of choice, hereby give my consent to be included as a participant in ___ ” (title of the
study)
(1) I have read and understood this consent form and the information provided to me.
(2) I have had the consent document explained to me.
(3) I have been explained about the nature of the study.
(4)   I have been explained about my rights and responsibilities by the investigator.
(5) I have informed the investigator of all the treatments I am taking or have taken in the past
______ months including any native (alternative) treatments.
(6) I have been advised about the risks associated with my participation in the study.?
(7) I agree to cooperate with the investigator and I will inform him/her immediately if I suffer
unusual symptoms.?
(8) I have not participated in any research study within the past _____ month(s).?
(9) [I have not donated blood within the past _____months -- Add if the study involves extensive
blood sampling]?
(10)  I am aware of the fact that I can opt out of the study at any time without having to give any
reason and this will not affect my future treatment in the hospital.?
(11)  I am also aware that the investigators may terminate my participation in the study at any
time, for any reason, without my consent.?
(12)  I hereby give permission to the investigators to release the information obtained from me as
result of participation in this study to the sponsors, regulatory authorities, Government
agencies, and ethics committee. I understand that they may inspect my original records.
(13)  I understand that my identity will be kept confidential if my data are publicly presented.
(14)  I have had my questions answered to my satisfaction.
(15)  I consent voluntarily to participate as a participant in the  research study.
I am aware, that if I have any questions during this study, I should contact the investigators.
By  signing this consent from, I attest that the information given in this document has been clearly
explained to me and understood by me. I will be given a copy of this  consent document.
For adult participants
Name and signature / thumb impression of the participant (or legal representative if participant
incompetent):
(Name) __________________________(Signature)___________________ Date: __________
Name and signature of impartial witness (required for illiterate patients):
(Name) __________________________ (Signature)___________________ Date:__________
Address and contact number of the impartial witness: _________________________________
Name and signature of the Investigator or his representative obtaining consent:
(Name) __________________________ (Signature)___________________ (Date)__________
Name and signature / thumb impression of the participant’s parent(s) (or legal representative):
(Name) __________________________ (Signature)______________ Date: __________
(Name) __________________________ (Signature)______________ Date: __________
Name and signature of impartial witness (required if parents of participant child illiterate):
(Name) __________________________ (Signature)______________ Date:__________
Address and contact number of the impartial witness: ___________________
______________________________________________
Name and signature of the Investigator or his representative obtaining consent:
(Name) __________________________ (Signature)_________________ (Date)__________
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